LAVERDIA-CA1
(verdinexor)

The first FDA Conditionally Approved Oral Tablet to Treat Lymphoma in Dogs.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526

Introducing a breakthrough oral treatment for canine lymphoma

The first FDA conditionally approved oral tablet to treat lymphoma in dogs

The power to fight cancer is now in your hands

LAVERDIA-CA1

verdinexor

LEARN MORE

Convenient

Treat your dog in the comfort of home

Affordable

Priced to make treatment possible for more pets

Safe

Studies show only mild or moderate side effects

Targeted

Blocks the nuclear export of tumor suppressor proteins resulting in cancer death

Effective

Proven to fight even the most aggressive form of lymphoma

Treat Your Dog Anywhere

The world's first targeted lymphoma treatment in pill form makes it possible for you to treat your dog anywhere.

Fights All Stages and
Types of Lymphoma

  • Proven effective against the most common B-cell and aggressive T-cell lymphomas
  • First-line therapy for newly diagnosed cases
  • Rescue therapy when traditional chemotherapy stops working

Targets Cancer
at the Core

LAVERDIA-CA1 uses novel SINE technology to help keep Tumor Suppressor Proteins in the nucleus of cancer cells to help fight lymphoma.

See how it works

Designed to be Harsh on Cancer, Not on Your Dog

Side effects are mild to moderate and effectively managed without hospitalization. Common side effects are anorexia, diarrhea, lethargy, and vomiting.

Please see package insert for important safety information.


Anyone who administers LAVERDIA-CA1 should wear protective chemotherapy resistant gloves and wash hands immediately and thoroughly with soap and water after handling LAVERDIA-CA1. See the Client Information Sheet for complete details and helpful instructions.

Expanding access
to cancer care

Breakthrough SINE technology targets cancer at the core

Dog Laying In Bed

Canine lymphoma is one of the most commonly encountered neoplasms and is the most untreated canine cancer.

1 in 5 Dogs Icon

Common

1 in 5 cancer diagnosesis lymphoma
Clock Icon

Devastating

30-day life expectancywithout chemo treatment
8 in 10 Dogs Icon

Undertreated

8 in 10 dogs are untreated due toside effects and costs over $5k

Articles in the Anivive library

Common Symptoms of Canine Lymphoma
Anivive Team
What to ask your Oncologist
Anivive Team

9 questions to guide your discussion with your dog’s oncologist

When Treatment Starts, Play Doesn’t Have to Stop
Anivive Team

How to keep your dog engaged and moving during cancer treatment when they may be feeling down

Helping Children Cope When the Family Dog Has Cancer
Anivive Team

The news is hard for everyone to accept. Here are tips from our veterinarians on how your family can process the information in a healthy way.

LAVERDIA-CA1 is a Selective Inhibitor of Nuclear Export (SINE)

1st Targeted Inhibitor

SINE technology kills cancer cells while sparing most healthy cells

Inhibits Exportin 1 (XPO1)

Blocks the nuclear export of tumor suppressor proteins, helping restore natural anti-cancer defenses

Proven Efficacy

Clinical studies have demonstrated efficacy against B-cell and T-cell lymphoma - in both naïve and relapse cases

LAVERDIA-CA1 Starter Kit

If you’re a veterinarian interested in prescribing LAVERDIA-CA1 to your lymphoma patients, sign up to get started today.

LAVERDIA-CA1

verdinexor

Now available to
veterinarians